Physician profile
Scott Freeman
NPI 1508802752
$201,799.78
in general payments reported to CMS, 2019-2025
35 companies · $46K in 2025
The $46K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36K · 2022: $41K · 2023: $34K · 2024: $45K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Food and Beverage: $20K · Consulting Fee: $9,258 · Travel and Lodging: $6,873 · Education: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,810.00 |
| Food and Beverage | $19,620.96 |
| Consulting Fee | $9,257.50 |
| Travel and Lodging | $6,872.96 |
| Education | $309.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $56,430.35 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $33,177.16 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $27,814.43 | 2021-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $17,689.14 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Regeneron Healthcare Solutions, INC. | $17,303.08 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $14,039.22 | 2021-2025 | |
| Janssen Biotech, INC. | $7,519.55 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $6,542.54 | 2021-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $6,347.32 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $3,139.14 | 2021-2025 | |
| Leo Pharma INC. | $2,337.20 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Lilly USA, LLC | $2,211.21 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $1,807.64 | 2021-2025 | |
| Galderma Laboratories, L.P. | $894.86 | 2021-2025 | Epsolay, Nemluvio, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $781.78 | 2021-2025 | Siliq, Targretin, Duobrii |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $696.94 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $603.67 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $455.49 | 2022-2025 | Spevigo, Cyltezo |
| Almirall LLC | $393.94 | 2021-2025 | Seysara |
| Botanix Sb INC | $377.37 | 2025 | Sofdra |
| Janssen Scientific Affairs, LLC | $283.37 | 2021-2022 | |
| Eli Lilly and Company | $195.22 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Journey Medical Corporation | $168.23 | 2022-2025 | |
| Genentech USA, INC. | $146.47 | 2021-2024 | Actemra, Erivedge |
| Organon LLC | $74.50 | 2025 | Vtama |
| Ani Pharmaceuticals, INC. | $73.22 | 2025 | Veregen, Oxistat |
| Epi Health, LLC | $69.96 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $46.72 | 2021 | |
| Cipher Pharmaceuticals US LLC | $45.13 | 2025 | Spinosad, Natroba |
| Sebela Pharmaceuticals INC. | $45.10 | 2022-2023 | Naftin |
| Verrica Pharmaceuticals INC. | $24.20 | 2024 | Ycanth |
| Biofrontera INC. | $20.35 | 2021 | |
| Fresenius Kabi USA, LLC | $17.84 | 2024 | Idacio |
| Tempus Ai, INC | $15.80 | 2024 | Merlin Test |
| Allergan, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.